Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 4/20 | 0.64 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.64 |
| ▸ | PI4KA | P42356 | 1/20 | 0.64 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.64 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.64 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.64 |
| ▸ | FDPS | P14324 | 1/20 | 0.55 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.52 |
| ▸ | FGFR1 | P11362 | 7/20 | 0.52 |
| ▸ | FGFR4 | P22455 | 7/20 | 0.52 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.49 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.47 |
| ▸ | TMIGD3 | P0DMS9 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | CDK1 | P06493 | 1/20 | 0.45 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.45 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.45 |
| ▸ | CDK2 | P24941 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23436498 | 0.86 | ADORA2A (0.66) | ADORA2AADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL8982987 | 0.83 | ADORA2A (0.68) | ADORA2AADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL31331791 | 0.83 | ADORA2A (0.68) | ADORA2AADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL11248513 | 0.82 | FDPS (0.52) | ADORA2AADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL10589823 | 0.82 | ADORA2A (0.61) | ADORA2AADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL12653733 | 0.82 | FDPS (0.49) | ADORA2AADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL23323404 | 0.81 | FDPS (0.63) | ADORA2AADORA1FDPSP2RX7FGFR1 | |
| SCHEMBL11723304 | 0.81 | FDPS (0.51) | ADORA2AADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL11597739 | 0.80 | FDPS (0.58) | ADORA2AADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL11899180 | 0.80 | ADORA2A (0.60) | ADORA2AADORA1PI4KAPI4K2BPI4K2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118638119-B | Pyrazole purine herbicide safener as well as preparation method and application thereof | 东北农业大学 | 2025-02-28 | — | — | CN | disclosed |
| CN-118638119-A | Pyrazole purine herbicide safener as well as preparation method and application thereof | 东北农业大学 | 2024-09-13 | — | — | CN | disclosed |
| US-20240182475-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH HYPERMINERALIZATION | Université de Lausanne (CH) | 2024-06-06 | — | — | US | disclosed |
| CN-117430609-B | Purine derivative compound, preparation method and application thereof | 东北农业大学 | 2024-05-24 | — | — | CN | disclosed |
| EP-4308117-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH HYPERMINERALIZATION | Université de Lausanne (CH) | 2024-01-24 | — | — | EP | disclosed |
| CN-117430609-A | Purine derivative compound, preparation method and application thereof | 东北农业大学 | 2024-01-23 | — | — | CN | disclosed |
| WO-2022194953-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH HYPERMINERALIZATION | Université de Lausanne (CH) | 2022-09-22 | — | — | WO | disclosed |
| EP-3436017-B1 | PURINE INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | MERCK SHARP & DOHME (US) | 2020-09-23 | — | — | EP | disclosed |
| US-10544147-B2 | Purine inhibitors of human phosphatidylinositol 3-kinase delta | MERCK SHARP & DOHME CORP. (US) | 2020-01-28 | — | — | US | disclosed |
| US-20190328762-A1 | COMBINATIONS OF PD-1 ANTAGONISTS AND CYCLIC DINUCLEOTIDE STING AGONISTS FOR CANCER TREATMENT | MERCK SHARP & DOHME CORP. (US) | 2019-10-31 | — | — | US | disclosed |
| EP-2920172-A1 | PURINE INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | Merck Sharp & Dohme Corp. (US) | 2015-09-23 | — | — | EP | disclosed |
| WO-2014075392-A1 | PURINE INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | MERCK SHARP & DOHME CORP. (US) | 2014-05-22 | — | — | WO | disclosed |
| WO-2014075393-A1 | PURINE INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | MERCK SHARP & DOHME CORP. (US) | 2014-05-22 | — | — | WO | disclosed |
| WO-2014075393-A1 | PURINE INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | MERCK SHARP & DOHME CORP. (US) | 2014-05-22 | — | — | WO | disclosed |
| WO-2014023083-A1 | PI3Kδ INHIBITOR | 山东亨利医药科技有限责任公司 (CN) | 2014-02-13 | — | — | WO | disclosed |
| CN-1724549-A | Nucleoside phosphonate compound | INST OF RADIOACTIVE MEDICINE A (CN) | 2006-01-25 | — | — | CN | disclosed |
| EP-0802914-B1 | ARYL- AND HETEROARYL- PURINE AND PYRIDOPYRIMIDINE DERIVATIVES | PHARMACIA & UPJOHN SPA (IT) | 2001-06-06 | — | — | EP | disclosed |
| US-5965563-A | NOVEL PURINE DERIVATIVES SUCH AS N6-(2-OXINDOL-5-YL) ADENINE, METHODS OF SYNTHESIZING THEM; USE AS TYROSINE KINASE INHIBITORS | PHARMACIA & UPJOHN S.P.A. (IT) | 1999-10-12 | — | — | US | disclosed |
| EP-0802914-A1 | ARYL AND HETEROARYL PURINE COMPOUNDS | PHARMACIA & UPJOHN S.p.A. (IT) | 1997-10-29 | — | — | EP | disclosed |
| WO-1997018212-A1 | ARYL AND HETEROARYL PURINE COMPOUNDS | PHARMACIA & UPJOHN S.P.A. (IT) | 1997-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240182475-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH HYPERMINERALIZATION | CTH, CBS, GAA | ADORA2A 2488/4885ADORA1 2882/4885PI4KA 3301/4885 |
| US-10544147-B2 | Purine inhibitors of human phosphatidylinositol 3-kinase delta | PIK3CD, PIK3CA, PI4KA | ADORA2A 82/4885ADORA1 51/4885PI4KA 3/4885 |
| US-20190328762-A1 | COMBINATIONS OF PD-1 ANTAGONISTS AND CYCLIC DINUCLEOTIDE STING AGONISTS FOR CANCER TREATMENT | STING1, CGAS, MAVS | ADORA2A 228/4885ADORA1 314/4885PI4KA 770/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.